A recent study suggests that patients who discontinue new slimming jabs like Mounjaro or Wegovy can put back on shed pounds far faster than those who end traditional lifestyle plans.
Findings released in a major medical journal shows that while obese people often shed substantial amounts of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying such treatments need to be informed of the potential of fast weight regain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of recovery implies a return to starting weight in about 18 months.
Analyzing Approaches
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through diet and exercise typically have a slower creep back—around 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists believe the mode of action of the injections is key to understanding the heightened weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
Health authorities advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts say that, due to the high risk of weight regain, the therapy should be considered long-term.
This view is reinforced by pharmaceutical companies, who state that the results "underscore the chronic character of excess weight," comparing it to managing diseases like diabetes.
User Accounts
People who have stopped the jabs explain a sudden return of hunger.
"I experienced something activating and you become starving," described an individual.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural changes during therapy.
Growing Use
Recent estimates suggest that millions of adults in the UK have tried these injections in the past year, with demand being substantial.
- Use is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and lasting health benefits likely depends on ongoing behavioural management.
